Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:06:25.250Z.
Calculation as of: 2026-10-06T14:06:25.250Z.
Quote observation: 2026-10-06T14:05:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5259cb07e2fbb96f0e8f0a81153900e7454c243d03e5865b91db876a0b9f3ffb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$434.84M
EBITDA Yield
230.74%
TTM Avg
150.45%
3Y Avg
150.45%
5Y Avg
150.45%
Market Cap
$412.14M
EBITDA Yield
N/A
TTM Avg
951.70%
3Y Avg
394.96%
5Y Avg
394.96%
Market Cap
$411.45M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$457.20M
EBITDA Yield
N/A
TTM Avg
8.61%
3Y Avg
13.81%
5Y Avg
19.64%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | $432.00M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $434.84M | 230.74% | 150.45% | 150.45% | 150.45% |
| Assembly Biosciences, Inc. (ASMB)vs › | $443.61M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $412.76M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | N/A | 951.70% | 394.96% | 394.96% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $411.45M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $408.54M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $457.20M | N/A | 8.61% | 13.81% | 19.64% |
| NeoGenomics, Inc. (NEO)vs › | $460.20M | N/A | 1.44% | 5.28% | 7.05% |
| Kamada Ltd. (KMDA)vs › | $460.98M | 9.73% | 10.23% | 10.38% | 8.34% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
